"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Pt. 1 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Dunsire takes stock of Millennium's business development mandate as part of a global organization, its clinical pipeline and other operational changes since the firm became the Takeda Oncology company.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Pt. 2 Of 2)
Dunsire talks about what it takes for Millennium, Takeda's Oncology program, to operate a a stand-alone unit within the Japanese pharma, and strategies to retain key staff and culture.